You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. An Opioid/Cannabinoid Analgesic that Boosts Pain Relief and Blocks Opiate Reward

    SBC: ElSohly Laboratories, Incorporated            Topic: NIDA

    Project Summary Abuse of prescription opioids and fatalities related to their misuse have increased sharply in recent yearsmaking the development of pain medications with reduced abuse potential a major public health priorityWhen combinedopioids and cannabinoidCBreceptor agonists show analgesic effects appear to be at least additive in a number of pain modelsCannabidiolCBDalthough much less psycho ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. A Preclinical Trial of Therapeutic Angiogenesis Plus Angioplasty and Stenting for Renal Vascular Disease

    SBC: Leflore Technologies LLC            Topic: 400

    Abstract Chronic kidney disease CKD is a progressive disorder affecting almost of the general population and this disease has shown a relentless growth over the past decades Patients with CKD have higher rates of hospitalization greater mortality shorter life expectancy and their healthcare costs are up to times more expensive than non CKD patients Thus treatments to slow halt ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Bioassay Methods for Standardization of Immune Enhancing Dietary Supplements

    SBC: PSI (Phytochemical Services, Incorporated)            Topic: 213

    DESCRIPTION provided by applicant Clinical trials testing the potential health benefits of immune enhancing dietary supplements have produced inconsistent results A major problem contributing to these inconsistent outcomes is that these studies have used a wide variety of poorly characterized products Attempts to solve this product quality control problem using chemical standardization method ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

    SBC: ElSohly Laboratories, Incorporated            Topic: N/A

    DESCRIPTION (provided by applicant): The long term objectives of this proposal are aimed at the development of new composition(s) to be used for the prophylactic treatment/prevention of poison ivy contact dermatitis in sensitive individuals. Poison ivy/poison oak and another related species poison sumac are the main cause of occupational hazards for outdoor workers in the United States. Most of th ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

    SBC: ElSohly Laboratories, Incorporated            Topic: N/A

    DESCRIPTION (provided by applicant): Poison ivy/oak contact dermatitis is the most prevalent skin allergy in the United States, affecting gt50% of the adult population. The condition is the major cause of occupational hazard among outdoor workers in forestry, agriculture and firefighting, resulting in significant medical expenses and workers disability. Attempts have been made to provide prophyla ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Process for GMP Production of Natural THC and CBD

    SBC: ElSohly Laboratories, Incorporated            Topic: R41

    Development Process for Production of Natural THC and CBD AbstractTetrahydrocannabinolTHCand cannabidiolCBDare two major constituents of the cannabis plant that have pharmacological properties with potential therapeutic value in several disease conditionsWhileTHC has already been in use clinically for two indicationsnausea and vomiting in cancer patients receiving chemotherapy and appetite stimula ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Radiation Hard 4H-SiC Power Switches and Rectifiers for Circuit Applications In Harsh Environments

    SBC: SemiSouth Laboratories            Topic: MDA04T019

    ABSTRACT: Several new high-power, long range radar systems are under development for near-term upgrades or fielding by MDA, Navy, and Marine Corps, which will use High Voltage GaAs or new WBG Semiconductors (SiC, GaN) in the transmitter/receiver. These systems will require compact, efficient, temperature tolerant power supplies and converters typically requiring a 600 V class of power devices. ...

    STTR Phase II 2005 Department of DefenseMissile Defense Agency
  8. Development of Radiation Hard 4H-SiC Power Switches and Rectifiers for Circuit Applications In Harsh Environments

    SBC: SemiSouth Laboratories            Topic: MDA04T019

    SiC power switch devices such as Vertical Junction Field Effect Transistors (VJFETs) and Metal Oxide Semiconductor Field Effect Transistors (MOSFETs) are being developed for power conditioning applications in a variety of rugged environments. While the SiC devices have been well characterized for high-temperature behavior, much less data is available for radiation effects, including gamma and pro ...

    STTR Phase I 2004 Department of DefenseMissile Defense Agency
  9. Development of Tetrahydrocannabinol Prodrugs for Topical Treatment of Glaucoma

    SBC: ElSohly Laboratories, Incorporated            Topic: NEI

    DESCRIPTION (provided by applicant): Currently, FDA approved clinical applications of 9-Tetrahydrocannabinol (THC) include control of nausea and vomiting associated with chemotherapy and for appetite stimulation for AIDS patients suffering from anorexia and wasting syndrome. However, THC also has significant potential in the treatment of glaucoma, the second largest cause of blindness, by dec ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Improving treatment options and outcomes in fungal keratitis

    SBC: TranZ Biosciences LLC            Topic: N

    ABSTRACT Fungal keratitisprimarily caused by CandidaFusariumor Aspergillus speciesis a leading cause of blindness among corneal diseasesAmphotericin BAmBremains the gold standard in the treatment of Candida keratitis and is also the fallback option for other corneal fungal infectionsAlthough widely used off label in ocular infectionsophthalmic AmB formulations are not available commerciallyThe com ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government